| UHC Commercial Medical & Drug | Gonadotropin Releasing Hormone Analogs – Commercial Medical Benefit Drug Policy | 2025-07-01 |
| UHC Commercial Medical & Drug | Korsuva® (Difelikefalin) – Commercial Medical Benefit Drug Policy | 2025-07-01 |
| UHC Commercial Medical & Drug | Niktimvo™ (Axatilimab-Csfr) – Commercial Medical Benefit Drug Policy | 2025-07-01 |
| UHC Commercial Medical & Drug | Saphnelo® (Anifrolumab-Fnia) – Commercial Medical Benefit Drug Policy | 2025-07-01 |
| UHC Commercial Medical & Drug | Scenesse® (Afamelanotide) – Commercial Medical Benefit Drug Policy | 2025-07-01 |
| UHC Commercial Medical & Drug | Spevigo® (Spesolimab-Sbzo) – Commercial Medical Benefit Drug Policy | 2025-07-01 |
| UHC Commercial Medical & Drug | Viltepso® (Viltolarsen) – Commercial Medical Benefit Drug Policy | 2025-07-01 |
| UHC Commercial Medical & Drug | Vyondys 53® (Golodirsen) – Commercial Medical Benefit Drug Policy | 2025-07-01 |
| Ambetter Health Mississippi Magnolia Clinical | Intradiscal Steroid Injections for Pain Management | 2025-07-01 |
| Ambetter Health Mississippi Magnolia Clinical | Sacroiliac Joint Interventions for Pain Management | 2025-07-01 |